Marcus Ballinger

Marcus Ballinger is currently the Global Development Lead for Lung and Head & Neck Cancer Immunotherapy at Genentech, where they lead the Tecentriq program. With a PhD in Biochemistry from the University of Wisconsin-Madison, Marcus has held various leadership positions in the biopharmaceutical industry, including roles at Exelixis and Sunesis Pharmaceuticals. Prior to their current position, they served as Group Clinical Science Director at Genentech from 2012 to 2020 and held a postdoctoral position in Protein Engineering at Genentech from 1993 to 1996. Marcus's diverse experience spans over two decades in clinical science and drug discovery.